Natera, Inc. NTRA
Natera, Inc. (Nasdaq: NTRA) is a diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Nov 5, 2026completed enrollment Prospective colorectal cancer screening study FIND-CRC fully enrolled with 30K patients in PMA cohort, progressing toward FDA-enabling readout.
Prospective screening study fully enrolled, with 30K patients in PMA cohort.
Filing - Nov 5, 2026started AFT-70 NAVIGATE launched, a Signatera-guided phase 3 trial for adjuvant breast cancer de-escalation, expecting to enroll over 2,000 patients.
>2,000 patients expected to enroll ~200 sites in the U.S. and internationally 4-yr DRFS primary endpoint (non-inferiority)
Filing - Nov 5, 2026positive Real-world study of 125 liver cancer patients showed Signatera outperformed AFP with 83% vs 42% longitudinal sensitivity, 100% specificity, and 7.9 vs 2.2 month median lead time over imaging.
83% vs 42% longitudinal sensitivity, Signatera vs. AFP 100% longitudinal specificity 7.9 vs 2.2 mo median lead time over imaging, Signatera vs. AFP (up to 16.5 months)
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.